TrialThe Lancet. Oncology2014

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.

Arun Rajan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.